Deutsche Bank’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Deutsche Bank’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-19,154	Closed	-$26K	–	5777
2018 Q2	$26K	Sell	19,154 -20,746	-52%	-$31.8K	﹤0.01%	4959
2018 Q1	$57K	Sell	39,900 -26,280	-40%	-$54.9K	﹤0.01%	4712
2017 Q4	$148K	Buy	66,180 +34,739	+110%	+$87.9K	﹤0.01%	4136
2017 Q3	$106K	Sell	31,441 -3,973	-11%	-$13.4K	﹤0.01%	4148
2017 Q2	$124K	Buy	35,414 +27,737	+361%	+$91.4K	﹤0.01%	4134
2017 Q1	$25K	Sell	7,677 -10,680	-58%	-$41.5K	﹤0.01%	4452
2016 Q4	$83K	Buy	18,357 +5,022	+38%	+$20.7K	﹤0.01%	4169
2016 Q3	$55K	Buy	13,335 +265	+2%	+$857	﹤0.01%	4187
2016 Q2	$31K	Buy	13,070 +1,937	+17%	+$7K	﹤0.01%	4613
2016 Q1	$52K	Sell	11,133 -1,044	-9%	-$4.04K	﹤0.01%	4308
2015 Q4	$46K	Sell	12,177 -298	-2%	-$1.37K	﹤0.01%	4442
2015 Q3	$48K	Buy	12,475 +9,964	+397%	+$45.8K	﹤0.01%	4479
2015 Q2	$11K	Buy	+2,511	New	+$24.1K	﹤0.01%	5050

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deutsche Bank's AST Position: Q3 2018 in Review

Deutsche Bank sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2018, closing a stake of 19,154 shares — an estimated $26K sold.

Deutsche Bank first reported a position in AST in Q2 2015 and held it in 13 quarters. The position peaked at $148K in Q4 2017. 54 funds tracked by Wall St. Rank hold AST as of Q3 2018.

Deutsche Bank reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2018 after selling out during the quarter.
Deutsche Bank sold 19,154 Asterias Biotherapeutics Inc. Series A shares in Q3 2018, an estimated $26K.
Deutsche Bank first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and held it in 13 quarters.
Deutsche Bank's Asterias Biotherapeutics Inc. Series A position peaked at $148K in Q4 2017.
54 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2018.

Based on Deutsche Bank's 13F filing for Q3 2018, filed 14 Nov 2018.